camoteskimab

{
  "id": "MLC-T-ONC-012208",
  "term": "camoteskimab",
  "field": "Oncology and biomedicine",
  "definition": "A human immunoglobulin G1 (IgG1) monoclonal antibody against the pro-inflammatory cytokine interleukin-18 (IL-18), with potential anti-inflammatory and antineoplastic activities. Upon administration, camoteskimab selectively targets and binds to IL-18, thereby inhibiting IL-18-mediated signaling and inflammation mediated by this pathway. In addition, this may inhibit IL-18-mediated immunosuppression in the multiple myeloma microenvironment. IL-18 is a member of the interleukin-1 (IL-1) cytokine superfamily. Elevated IL-18 level is associated with disease progression and poor prognosis in multiple myeloma.",
  "synonyms": [
    "anti-IL-18 monoclonal antibody CERC-007"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/camoteskimab/"
}